Here, we demonstrated that the loss of PDCD10 in GBM cells reduced sensitivity to TMZ during the treatment phase, and largely promoted the regrowth of resistant GBM cells in TMZ in the post-treatment phase. The gene discussed is PDCD10; the disease is glioblastoma.